Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Pre-Cancerous Dysplasia Clear all

Completed Not applicable Interventional

Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions

NCT00507182

View directory record Official record

Conditions: Oral Cancer
Interventions: Fluorescence Spectroscopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 18, 2018 · Synced May 21, 2026, 10:50 PM EDT

Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264

View directory record Official record

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 13, 2025 · Synced May 21, 2026, 10:50 PM EDT

Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684

View directory record Official record

Conditions: Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions: VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000; Biological · Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more

Source: ClinicalTrials.gov public record

Updated Aug 24, 2023 · Synced May 21, 2026, 10:50 PM EDT

Recruiting Phase 2 Interventional

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744

View directory record Official record

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only

Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated Oct 1, 2025 · Synced May 21, 2026, 10:50 PM EDT

Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559

View directory record Official record

Conditions: HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions: DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod; Biological · Device · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only

Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 8, 2018 · Synced May 21, 2026, 10:50 PM EDT